PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩30 per share · Prices as of the 2026-10-02 close
Having returned to profit in 2024–2025 after a 2023 loss, Kukje Pharmaceutical is pursuing a KRW 55.5 billion capacity expansion while facing generic drug price-cut risk.
2025 consolidated revenue rose 12.2% to KRW 175.5bn, but operating margin fell from 4.3% to 3.5%
After a Q4 2025 loss, the company posted two consecutive profitable quarters in Q1–Q2 2026
Eye drops account for roughly 26–31% of revenue, led by the Qualon ophthalmic product
KRW 55.52bn investment at the Ansan plant targets a 133% increase in eye-drop output and 100% in tablets/capsules
Government plans to lower the generic drug pricing benchmark from 53.55% to 45% pose a margin risk
Kukje Pharmaceutical is a mid-tier Korean drugmaker founded in 1959, built primarily around prescription (ETC) products. The company has built strong competitiveness based on long experience and technology in ophthalmic disease treatments and cephalosporin antibiotics.
Its product lineup is led by tablets, with eye drops as the second-largest category by revenue.
Eye drops are Kukje's core business, ranking second after tablets at roughly 26% of revenue, and last year eye-drop sales jumped 14.8% to about KRW 45.5 billion, driven by the Qualon ophthalmic solution used for corneal epithelial disorders and dry eye.
The company also reaffirmed its position in the ophthalmology market by launching an improved dry-eye drug branded Rebaeye using proprietary patented technology, and has recently expanded into chronic disease areas such as diabetes treatments.
On distribution, the company achieved revenue growth after adopting a CSO (contract sales organization) model, but profitability has deteriorated as commission payments have increased SG&A costs.
On governance, through year-end 2025 executive appointments, third-generation owner Nam Tae-hoon was promoted to vice chairman, strengthening the third-generation leadership structure roughly nine years after he first became CEO in 2017.
However, Vice Chairman Nam's personal shareholding stands at a low 2.12%, leaving the need to secure funding to strengthen control as an ongoing task.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩45B | ₩3.5B | 7.8% |
| 2025Q3 | ₩45.6B | ₩1.9B | 4.2% |
| 2025Q4 | ₩43.3B | -₩1.5B | −3.6% |
| 2026Q1 | ₩44B | ₩2B | 4.5% |
| 2026Q2 | ₩48.3B | ₩2.1B | 4.4% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩126.6B | ₩5.3B | ₩3.6B | 4.2% | 4.8% | 84.4% |
| 2023 | ₩135.4B | -₩2B | -₩8.4B | −1.5% | −9.9% | 92.2% |
| 2024 | ₩156.5B | ₩6.7B | ₩5.2B | 4.3% | 5.8% | 84.9% |
| 2025 | ₩175.5B | ₩6.2B | ₩5.7B | 3.5% | 5.8% | 86.6% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
2025 consolidated revenue reached KRW 175.50 billion, up 12.2% from KRW 156.46 billion in 2024, the highest among the four years reviewed. However, operating profit fell to KRW 6.18 billion from KRW 6.70 billion the prior year, and operating margin declined from 4.3% to 3.5%.
Owners' net profit actually rose to KRW 5.70 billion from KRW 5.21 billion, suggesting other factors partly offset the operating profit decline.
In 2022 the company posted revenue of KRW 126.58 billion with operating profit of KRW 5.27 billion and owners' net profit of KRW 3.56 billion, but in 2023, despite revenue rising to KRW 135.37 billion, it swung to an operating loss of KRW 1.99 billion and a net loss of KRW 8.42 billion.
The company returned to profitability for two consecutive years in 2024 and 2025, though margins have not fully recovered to 2022 levels. On a quarterly basis, Q4 2025 saw another loss, with an operating loss of KRW 1.54 billion and a net loss of KRW 0.73 billion.
It then recovered in Q1 2026 (operating profit of KRW 1.97 billion, net profit of KRW 2.15 billion) and Q2 2026 (operating profit of KRW 2.13 billion, net profit of KRW 1.67 billion), extending two straight profitable quarters.
Over the trailing four quarters (Q3 2025–Q2 2026), owners' net profit totaled KRW 5.00 billion, though quarter-to-quarter volatility remains notable.
The Korean pharmaceutical market remains heavily reliant on generics; while large drugmakers grow through new drugs and biosimilars, mid-sized firms like Kukje Pharmaceutical continue to rely on a generics- and improved-drug-centered business model.
The government's plan to lower the generic drug pricing benchmark from 53.55% to 45% is expected to squeeze profitability, with small and mid-sized pharmaceutical companies that rely heavily on CSOs likely to be hit harder.
Indeed, Kukje Pharmaceutical has seen its commission expenses rise 17.3% from KRW 49.9 billion to KRW 58.5 billion, driving up overall SG&A costs.
On the raw material side, a prolonged naphtha supply disruption stemming from Middle East geopolitical risk could raise the cost burden for medical plastic products such as single-use eye-drop containers.
Conversely, globally, the expiration of patents on numerous major original brands between 2023 and 2027 is seen as an opportunity for generic drug growth, with the patent-expiry market estimated at over KRW 2.587 trillion over the next five years.
That said, aggregate operating profit at listed Korean pharma and biotech companies rose more than 40% year-on-year in Q2 2026, a trend largely driven by companies with large new-drug and biotech pipelines, a growth path that differs from Kukje Pharmaceutical's generic-focused eye drop and antibiotic business.
In the eye-drop segment, rising production facility utilization pressure has made capacity expansion a common theme across the industry.
Kukje Pharmaceutical has set 'Delivering Key Projects' as its 2026 management theme and is working to secure a foundation for future growth. The plan includes building a new eye-drop plant, strengthening improved-drug R&D, and cultivating key products to pursue sustainable growth.
At the March annual shareholders' meeting, agenda items including financial statement approval and director appointments passed as proposed, and the board was reorganized with finance, legal, and pharmaceutical regulation experts joining the audit committee.
CEO Nam Tae-hoon emphasized execution capability at the meeting, noting that intensifying generic drug price-cut policy is expected to reshape the operating environment across the industry.
On capacity, the company is investing KRW 55.52 billion to build new eye-drop and solid-dosage (tablet/capsule) production buildings and a warehouse at its Ansan plant, with the investment running through the end of September 2029.
Once complete, eye-drop production capacity is planned to increase by 133%, and tablet/capsule capacity by 100%.
The investment schedule starts with KRW 4.9 billion this year, followed by KRW 40 billion in 2027 and KRW 10.62 billion in 2028, with about 72% concentrated in 2027, and ahead of that, the company targets building an additional eye-drop production line by January 2027.
On R&D, the triple-combination improved glaucoma drug TFC-003 is in Phase 3 trials with a target of formal approval and launch in 2028, though the overall pipeline remains at an early stage with only two new drug candidates and three improved drug candidates, making near-term contributions unlikely.
Kukje Pharmaceutical's stock trades on an earnings base re-established after the company returned to profit in 2024–2025 following a 2023 loss, allowing profit-based valuation approaches that were not meaningful during the loss year.
The share price sits below net asset value per share, meaning it trades at a discount to book value. Cash dividends remain modest in scale, making the sustainability of the profit recovery a more relevant variable than the dividend yield itself.
Given that quarterly operating profit has swung between gains and losses, market valuation is likely to remain sensitive to each quarterly earnings release going forward.
With a large capacity-expansion investment underway, how the associated cost burden and eventual cost-efficiency gains flow through the financial statements will likely be a key reference point for assessment.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
The company emerged from a temporary Q4 2025 loss to post operating and net profit in both Q1 and Q2 2026. Revenue has also grown gradually each quarter, sustaining top-line expansion.
The eye-drop segment, buoyed by growth in its flagship products, is expanding its revenue share and has become an anchor for the earnings recovery.
The company plans to invest KRW 55.52 billion at its Ansan plant to raise eye-drop capacity by 133% and tablet/capsule capacity by 100%, aiming to replace aging equipment and improve cost competitiveness.
As revenue growth has outpaced existing utilization capacity, there is room for production efficiency gains once the expansion is complete.
The end-2025 promotion of third-generation owner Nam Tae-hoon to vice chairman clarified the succession structure, and the board strengthened its audit committee with finance, legal, and pharmaceutical regulation experts.
Such governance improvements may contribute over time to greater management transparency and a more structured decision-making process.
The government is pushing to lower the generic drug pricing benchmark from 53.55% to 45%, which could pressure profitability at Kukje Pharmaceutical given its generics-heavy revenue structure. Smaller companies with high CSO reliance are flagged as likely to be hit harder.
Commission payments rose 17.3% from KRW 49.9 billion in 2024 to KRW 58.5 billion in 2025, driving up SG&A and contributing to the operating margin decline from 4.3% to 3.5% in 2025. As long as the CSO-dependent distribution model persists, structural cost improvement may remain difficult.
A sudden return to losses, similar to Q4 2025, cannot be ruled out, and the KRW 55.5 billion expansion investment, concentrated in 2027, could add near-term financial strain. The pipeline remains at an early stage, meaning contributions from new drugs are unlikely to materialize in the near term.
If the government's proposed change to the generic drug pricing benchmark (from 53.55% to 45%) is finalized, margins relative to revenue could decline further. Policy changes related to CSO commissions also remain undecided, leaving uncertainty.
If naphtha supply becomes unstable due to Middle East geopolitical risk, costs for medical plastics such as single-use eye-drop containers could rise. The company has stated there has been no significant change so far, but a prolonged crisis could still have an impact.
Vice Chairman Nam's personal shareholding of only 2.12% means additional funding will be needed to strengthen control, and decisions made in that process could potentially affect shareholder value.
Expected filing date for the Q3 2026 quarterly report; worth checking whether the recovery since Q4 2025's temporary loss continued into the third quarter.
Target date for building an additional eye-drop production line at the Ansan plant; worth monitoring whether the line is completed on schedule and its initial capacity impact.
About 72% of the KRW 55.5 billion expansion investment is scheduled to be executed this year; worth watching its impact on the balance sheet and cash flow.
Target year for formal approval and launch of the triple-combination glaucoma drug TFC-003; worth confirming Phase 3 completion and regulatory approval progress.
Kukje Pharmaceutical returned to consecutive profitability in 2024–2025 after a 2023 loss, and continued that recovery with profitable Q1 and Q2 results in 2026.
However, its 2025 operating margin declined from the prior year due in part to CSO commission burdens, and the company posted another loss in Q4 2025, underscoring persistent quarterly volatility.
The eye-drop segment has become a core growth pillar with a rising revenue share, and the company plans to invest KRW 55.52 billion to substantially expand production capacity at its Ansan plant.
At the same time, the government's push to lower the generic drug pricing benchmark is flagged as a medium-term profitability risk. While the formalization of third-generation ownership has been accompanied by governance improvements, securing sufficient equity for succession remains an unresolved task.
Pipeline assets such as the improved glaucoma drug TFC-003 remain in clinical stages, making them more relevant to a medium-to-long-term view than near-term earnings. Investors may wish to monitor upcoming quarterly results, progress on the capacity expansion, and the finalization of generic pricing policy.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.